Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Liabilities and Shareholders Equity (2018 - 2025)

Historic Liabilities and Shareholders Equity for China SXT Pharmaceuticals (SXTC) over the last 8 years, with Q3 2025 value amounting to $26.4 million.

  • China SXT Pharmaceuticals' Liabilities and Shareholders Equity fell 1498.21% to $26.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $102.1 million, marking a year-over-year increase of 394.31%. This contributed to the annual value of $21.7 million for FY2025, which is 632.83% down from last year.
  • According to the latest figures from Q3 2025, China SXT Pharmaceuticals' Liabilities and Shareholders Equity is $26.4 million, which was down 1498.21% from $21.7 million recorded in Q1 2025.
  • In the past 5 years, China SXT Pharmaceuticals' Liabilities and Shareholders Equity registered a high of $34.5 million during Q1 2021, and its lowest value of $14.6 million during Q3 2023.
  • Moreover, its 5-year median value for Liabilities and Shareholders Equity was $24.7 million (2024), whereas its average is $25.9 million.
  • As far as peak fluctuations go, China SXT Pharmaceuticals' Liabilities and Shareholders Equity plummeted by 3423.31% in 2023, and later skyrocketed by 11248.56% in 2024.
  • China SXT Pharmaceuticals' Liabilities and Shareholders Equity (Quarter) stood at $22.7 million in 2021, then fell by 2.16% to $22.2 million in 2022, then plummeted by 34.23% to $14.6 million in 2023, then soared by 112.49% to $31.0 million in 2024, then dropped by 14.98% to $26.4 million in 2025.
  • Its Liabilities and Shareholders Equity was $26.4 million in Q3 2025, compared to $21.7 million in Q1 2025 and $31.0 million in Q3 2024.